NASDAQ : LABT
Lakewood-Amedex Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 473.94K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 473,938 |
| Enterprise Value | -4.01M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.37M |
| Shares Outstanding | 2.37M |
| Shares Change (YoY) | +27.02% |
| Shares Change (QoQ) | +102.96% |
| Owned by Insiders (%) | 51.19% |
| Owned by Institutions (%) | 5.38% |
| Float | 847,670 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.10 |
| P/TBV Ratio | 0.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.70 |
| Quick Ratio | 7.29 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.40 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -402.84% |
| Return on Assets (ROA) | -139.40% |
| Return on Invested Capital (ROIC) | -166.20% |
| Return on Capital Employed (ROCE) | -167.83% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.79M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.39 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 16.34 |
| Average Volume (20 Days) | 4,306,483 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 90,040 |
| Short Previous Month | 130,722 |
| Short % of Shares Out | 3.80% |
| Short % of Float | 10.62% |
| Short Ratio (days to cover) | 0.04 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.27M |
| Pretax Income | -7.35M |
| Net Income | -8.97M |
| EBITDA | -7.26M |
| EBIT | -7.27M |
| Earnings Per Share (EPS) | -$10.20 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.58M |
| Total Debt | 101,619 |
| Net Cash | 4.48M |
| Net Cash Per Share | $1.89 |
| Equity (Book Value) | 4.33M |
| Book Value Per Share | 2.00 |
| Working Capital | 4.22M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -3.49M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4,634 |
| Net Borrowing | n/a |
| Free Cash Flow | -3.49M |
| FCF Per Share | -$1.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.02% |
| Shareholder Yield | -27.02% |
| Earnings Yield | -5,099.98% |
| FCF Yield | -735.49% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.50 |
| Price Target Difference | 3,650.00% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 22, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |